Home


MENMS-M
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (2A, 2B, FMTC), MUTATION SCREEN, BLOOD

Test Code MENMS-M 
Test MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (2A, 2B, FMTC), MUTATION SCREEN, BLOOD 
Methodology DNA sequencing of exons 10,11,13,14,15, and 16 of the RET proto-oncogene 
Description Useful for confirmation of diagnosis of MEN 2A, 2B and FMTC and for documentation of germline mutation to distinguish familial MTC from sporadic MTC.

NOTE: This test, when ordered on Medicare patients, is subject to the Local Coverage Determination (LCD) policy "Molecular Diagnostics". Please verify that the diagnosis code (ICD-9) you have chosen demonstrates medical necessity for the test as documented in the physician's patient record. The carrier web site, CMS web site or the NorDx Limited Coverage Documentation Guide are available to assist you with this verification. A properly executed Advance Beneficiary Notice (ABN) must be submitted with the specimen if medical necessity is not demonstrated by the ICD-9 code chosen. 

Specimen All specimens should include a "Molecular Genetics Congenital Disorders Request Form" (Supply T245) with information including relevant clinical and family information. This form is supplied by NorDx. Specimens must arrive within 96 hours of draw.

BLOOD
Draw blood in a lavender-top (EDTA) tube(s) or a yellow-top (ACD) tube(s) and send 2.0 mL (minimum: 0.5 mL) of whole blood in original VACUTAINER(S). Invert several times to mix blood. Forward unprocessed whole blood promptly at ambient temperature only. 

Reference Values An interpretive report will be issued. 
Analytic Time 4 Days 
Day(s) Test Set Up Wednesday 
CPT Code(s) 81405